Niagen Bioscience, Inc. · NASDAQ:NAGE
Niagen Bioscience — ChromaDex — Investor Presentation (May 2015)
33 slides from Niagen Bioscience's investor presentation, May 27, 2015
Slide 1: ChromaDex Investor Presentation May 2015
ChromaDex. CONNECTION © i> Investor Presentation May 2015
Slide 2: Disclaimers
Disclaimers Safe Harbor ‘sprain end ar wien ool seman made frm tne one by repreverttves of vomaDax cata forvrd-oking statement” win he meaning ot Secon 27A ofthe Sees Ac of 1993, 05, ended and Sete 21 a te Ses Exchange At of 193 Foreningen elie eee vw abot ht re. Stoel ore net ie tr, not al eat 2013
Slide 3: Market Statistics
Market Statistics Ticker CDXC(OTCGX) Diluted Shares Outstanding 122.6m Key Shore Pcs of 5/5/2015) $121, are cop S00 ° 4: 52 Week High $1.72 Plus: Debt (4/4/2015) $3.1m Statistics = £090 le coon faa ‘Average Dally Volume (3 Mo.) 160,000 Enterprise Value $125m =e ess Bena Dr. Phillip Frost 15,252,937
Slide 4: ChromaDex at a Glance
ChromaDex® at a Glance Founded 1999 by CEO Frank Jaksch + Headquarters: Irvine, CA = + Analytical Laboratory: Boulder, CO ivine, CA - Acquired in April 2003 from NaPro BioTherapeutics ” bby, Regulatory Consulting: Rockville, MD - Acquired Spherix Consulting in December 2012 + Employees: Approximatel
Slide 5: ChromaDex Overview
ChromaDex Overview * ChromaDex is a leader in providing seamless, science-based solutions to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries. * Our unique business model gives us first-mover advantages in acquiring and commercializing valuable novel ingredient technol
Slide 6: With Years of Expertise, We Have Established Ourselves as a Leader
With 15 Years of Expertise, We Have Established Ourselves as a Leader in The Natural Products Chemistry Industry [12% CAGR since 2006 _ Well-Established { Customer Base * Largest phytochemical + Analytical testing of * Aglobal leader in | | | vin a | | | | | catalog in the world products for identit
Slide 7: ChromaDex's Unique Business Model Gives it First-mover Advantages
ChromaDex's Unique Business Model Gives it First-mover Advantages in Acquiring Patented Novel Ingredient Technologies ‘Access to Research Activity... Insight to Consumer Markets... Over 250 University & Research Institute customers Over 1500 Industry Customers | NBTY Me argu | % Dartmouth Cornell Un
Slide 8: ChromaDex Discovers, Acquires, & Develops Early-Stage Proprietary Novel Ingredient Technologies
ChromaDex Discovers, Acquires, & Develops Early-Stage Proprietary Novel Ingredient Technologies and Commercializes them in Multi-Billion-Dollar Markets Discover novel, early-stage Ingredient Technologies, leveraging intelligence ‘gained from activities of the natural products chemistry business Acqu
Slide 9: Novel Ingredient Market Opportunity
Novel Ingredient Market Opportunity Ingredient net sales were $6.9 million for FY 2014, an increase of 182%, compared to $2.4 million for FY 2013 ry (3) f fal 1 MLM: Multi-Level-Marketing ChromaDex Ys is 2 DTC: Direct To Consumer
Slide 10: ChromaDex's NIAGEN is the 1st and Only Commercially Available Nicotinamide Riboside
eo ChromaDex's NIAGEN® is the 1st and Only Commercially Available Nicotinamide Riboside Sere NIAGEN + ChromaDex launched NIAGEN® in May 2013. je Nicotinamide Riboside (NR) is a compound found naturally in milk and shown to boost nicotinamide adenine dinucleotide (NAD+) levels. NAD+ is a critical com
Slide 11: NR as a NAD+ Precursor
e NR as a NAD+ Precursor The Importance of NAD+ As organisms age, NAD+ loves drop, which loads to © decrease in mitochondrial healthy this In tum leads to numerous ‘age-related health issues. Low NAD+ levels limit the activity of a group of enzymes called sirtuins, which are believed to play key rol
Slide 12: First Human Clinical Study
r;) First Human Clinical Study Initial Results of First Study + Initial results of the first human clinical study for the company's NIAGEN® branded nicotinamide riboside (NR) met its primary endpoint. The results demonstrated that a single dose of NR resulted in statistically significant increases i
Slide 13: Collaborative Agreements with Numerous Prestigious Universities and Research Institutions
ChromaDex has Collaborative Agreements with Numerous Prestigious Universities and Research Institutions on NIAGEN® HARVARD ‘ i] MEDICAL SCHOOL ULB ia iersityin Sel Cornell University L om ) avo ‘ Massachusetts Ooo MONG Te BE WD Reseancu score OLYTECIINIGUE Technology ray NVESITY @O ixsrirure FEDERAL
Slide 14: NIAGEN Commercialization Opportunities in Multi-Billion-Dollar Markets
Infant Formulas Dietary | =~ Morket Size - $88 NIAGEN® is a era ee 3808 a fe Platform Ingredient a y/) Al Sport Norton - Morket Size - $58 Applicable in “~~ NIAGE } “aia c ‘alizati t Medical Foods [| ama ‘ommercialization Numerous ‘Market Size-$98 ||") | Opportunities in ‘ os Multi-Billion-Dollar Ph
Slide 15: Potential Pharmaceutical Opportunities
@ Potential Pharmaceutical Opportunities NIH Study + Results of a study conducted by the National Institutes of Health (NIH) in collaboration with ChromaDex published in November 2014 indicate that NR was effective at restoring NAD+ levels in mitochondria and rescuing phenotypes associated with a de
Slide 16: pTeroPure is ChromaDex's Commercialized, IP-backed, Clinically-Studied Pterostilbene
e pTeroPure® is ChromaDex's Commercialized, |P-backed, Clinically-Studied Branded pterostilbene Overview Pterostilbene is a phytoalexin (plant defense system) found naturally in blueberries, but only in limited quantities + Closely related to resveratrol (an antioxidant found in grapes) but with key
Slide 17: pTeroPure Evaluated in a Phase 2/3 Clinical Study
@ _pleroPure® was Evaluated in a Phase 2/3 Clinical Study Which Showed Statistically Significant Results for its Ability to Lower Blood Pressure Clinical trial completed at the University of Mississippi + Double-blind, randomized, placebo-controlled, IRB-reviewed + 80 patients, 4 arms. Eight-week du
Slide 18: Uses of pTeroPure in the Skincare and Sun Protection Markets
@ Uses of pTeroPure® in the Skincare and Sun Protection Markets Topical Pterostilbene Study + On April 3", 2015 The University of Valencia and Green Molecular, S.L. published a study indie: that pterostilbene prevented acute ultraviolet B radiation ("UVB"), radiation-induced inflammation and photoag
Slide 19: PURENERGY is ChromaDex's Patent Protected and Clinically Studied Caffeine Ingredient
@ PURENERGY® is ChromaDex’s Patent Protected and Clinically Studied Caffeine Ingredient = Jer$Puré + Caffeine = PLR, hewoy P a Overview + By cocrystallizing caffeine with ChromaDex’s pTeroPure® pterostilbene, caffeine’s energy boost is sustained for at least 6 hours!. PURENERGY ® also results in a m
Slide 20: PURENERGY Clinical Results - 2013
° PURENERGY® Clinical Results - 2013 The cross-over, clinical study compared the cocrystallized caffeine in PURENERGY® with ordinary caff Results of Study + PURENERGY” delivers almost 30% more caffeine into the blood than ordinary caffeine. + The rate of caffeine absorption is significantly slower w
Slide 21: Ingredient Technology Patent Status
Ingeediont Technology Potent Satis + Methods of monvfoctre + NAD biosymesie + Methods of production ‘Methods of production (2) ‘Axonal degeneration proteaion + Topical uses for skin heath + Optimized topical delivery NIAGEN. = plersPure ChromaDex® r 7 Kaisa a aia Ingredient * Compotion of mater + Co
Slide 22: Ingredient Development Pipeline
Ingredient Development Pipeline Product Projected Launch Pipeline Product 1 Immunity 2015 Pipeline Product 2 Beta-Glucan 2015 Pipeline Product 3 NAD Metabolite 2016 Pipeline Product 4 NAD Metabolite 2016 Pipeline Product 5 NAD Metabolite 2016 Pipeline Product 6 Liver Protection (combination w/ 2016
Slide 23: ChromaDex is Following the Model of Other Ingredient Technology Companies
ChromaDex is Following the Model of Other Ingredient Technology Companies MARTEK= Patented vegetarian Se omega-3 ingredient OCEAN: Fish Oil Omega-3 Ingredient fortitech @D NEPTUNE Kill Oil Omega-3 S chromadex &®o Acquired by DSM for $1.08B in 2010 6 solazyme Delveringipts Acquired by DSM for $550M i
Slide 24: ChromaDex Received Strategic Investment from DSM Venturing
ChromaDex Received Strategic Investment from DSM Venturing in October 2013 $2.5 million common stock investment at $0.85/share Demonstrated DSM's confidence in the future of ChromaDex as well as its unique business model of acquiring and commercializing novel DSM ingredient technologies mH SCIENCE.
Slide 25: Scientific Advisory Board
3 ~ChromaDex 2g ‘uli SCIENTIFIC ADVISORY BOARD Komberg Brenner Beudeker ‘German * ChromaDex established its first formal Scientific Advisory Board (SAB) in July 2014 * Nobel Laureate Professor Roger Kornberg joined as Chair * The other SAB members are: *+ Dr. Charles Brenner, Professor of Biochemist
Slide 26: ChromaDex Highlights
ChromaDex® Highlights * Addressable Ingredient Market Opportunity: Over $4 Billion Dollars (NIAGEN. ) — | pleréPure | ProC3G. | Senn agin’) { * ChromaDex® has announced our last four sequential quarters of record revenue | * Ingredient Patent Portfolio includes NIAGEN ®, PURENERGY ®, pTeroPure®, and
Slide 27: Additional Company Information
ChromaDex. CONNECTION Additional Company Information
Slide 28: ChromaDex Ingredient Technology Portfolio
ChromaDex Ingredient Technology Portfolio ‘Monetization lnicol_ “Dietery Food & Animal Skin Compound Supply Safety Pharma Development Supplements Beverage HealthCare Branded Ingredient ped Supe as 0_Heatth Gs pleréPure Vv e Vavvo 2 @®@ve000 ProC3G. ‘yond. 3 gicose Pipeline of Ni © chrom & oO & al mu
Slide 29: Statements of Operations
Statements of Operations! For the Three Month Periods Ended April 4,2015 and March 29, 2014 April, 2015 March 29, 2014 Sales, net $ S2e0971 S$ 3074138 Cost of sales 3333347 2,089,130 Gross profit 4927, 965,008 ‘Operating expenses: ‘Sales and marketing 585,777 464.567 ‘General and adminstratve 228783
Slide 30: Balance Sheets
Balance Sheets! ‘Api 4, 2015 and January 3, 2015, 142015 dmsary. 2018 assets Curent Ase ‘ $ aaisea s 3004750 Sade recevabie 2annass ” te00 708 Hes iastess = aocoan Propad expences anther assets sss) 2801 Total cert aseta Tose.ae8 sass ot Leasehols nrovenents and Eqvement net Tose 1.284000 Other Nonc
Slide 31: Statements of Cash Flows
Statements of Cash Flows! For the Three Month Periods Ended Apri 4,015 and March 29, 2014 March 29,2014 Cash Flows From Operating Activities Net loss, S (1025515) $ (1,848,016) ‘Adjustments to reconcile net loss tonet cash ‘sed in operating acts S708 1086763 Changes in operating assets and tabiltes:
Slide 32: Non-GAAP Presentation Reconciliation
Non-GAAP Presentation Reconciliation! Consolidated Statements of Operations Eets of Non-cash Charges associated with Consolidated Statements of Operations (US GAAP) ‘Sharebased Compensation Expense Excluding Sharebased Compensation (Non GAAP) For the 3 Month Periods Ended Ape. 4, 2015 and Muy. 28, 2
Slide 33: Contact Information
Contact Information ChromaDex Corporation 10005 Muirlands Blvd, Suite G Irvine, CA 92618 Phone: +1-949-419-0288 Fax: +1-949-419-0294 www.chromadex.com ‘Andrew Johnson Director of Investor Relations Phone: +1-949-419-0288 andrew|@chromadex.com